Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.8K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.8K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

449
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
449

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment.

The Lancet. Oncology·2026
Same author

International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards.

The Lancet. Oncology·2026
Same author

Development and Validation of a Multimodal AI-Based Model for Predicting Post-Prostatectomy Treatment Outcomes from Baseline Biparametric Prostate MRI.

medRxiv : the preprint server for health sciences·2026
Same author

Evaluating Clinically Significant Prostate Cancer with Pathology-Registered Radiomics: A Multi-Reader Assessment Using Lesion Diameter-based Simplified Segmentations on MRI.

Academic radiology·2026
Same author

Antitumoral immunity induced by gel ethanol ablation to treat unresectable colorectal cancer metastases in the liver.

PloS one·2026
Same author

Tumor-Targeted IL-12 (PDS01ADC) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Non-randomized Phase II Trial.

JCO oncology advances·2026

Related Experiment Video

Updated: Jan 4, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

608

18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy.

Esther Mena1, Maria Liza Lindenberg2, Ismail Baris Turkbey2

  • 1Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland esther.menagonzalez@nih.gov.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|November 3, 2019
PubMed
Summary

18F-DCFPyL PET/CT imaging shows high detection rates for recurrent prostate cancer. This PSMA-targeted PET agent is effective even at low PSA levels, aiding in early detection and management.

Keywords:
DCFPyLPETPSMAbiochemical recurrenceprostate cancer

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.5K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.0K

Related Experiment Videos

Last Updated: Jan 4, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

608
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.5K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.0K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiochemistry

Background:

  • Biochemical recurrence of prostate cancer after primary local therapy often presents challenges in detection using conventional imaging.
  • Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) agents offer a promising avenue for improved diagnostic accuracy.

Purpose of the Study:

  • To evaluate the lesion detection rate of 18F-DCFPyL PET/CT in patients with biochemically relapsed prostate cancer following primary local treatment.
  • To correlate detection rates with prostate-specific antigen (PSA) levels, PSA kinetics, and primary tumor characteristics.

Main Methods:

  • A prospective study involving 90 patients with biochemical recurrence and negative conventional imaging after radical prostatectomy, radiation, or both.
  • Patients underwent whole-body 18F-DCFPyL PET/CT scans.
  • Analysis of lesion detection rates in relation to PSA levels, PSA doubling time, PSA velocity, and primary tumor grade.

Main Results:

  • 18F-DCFPyL PET/CT detected recurrence in 77.8% of patients, identifying 287 lesions (prostate bed, lymph nodes, distant sites).
  • Detection rates increased with PSA levels, showing 47.6% at >0.2 to <0.5 ng/mL and 94% at ≥2.0 ng/mL.
  • In postsurgical patients, PSA parameters correlated with PET results, suggesting prognostic value. Histopathology confirmed recurrence in 40% of positive scans, with a high positive predictive value.

Conclusions:

  • 18F-DCFPyL PET/CT demonstrates high detection rates for biochemically recurrent prostate cancer, significantly impacting clinical management, especially at low PSA levels (<0.5 ng/mL).
  • The correlation with PSA kinetics in postsurgical patients indicates potential prognostic value.
  • 18F-DCFPyL PET/CT is a highly promising tool for accurately localizing recurrent prostate cancer sites.